Bausch + Lomb Corporation

Toronto Stock Exchange BLCO.TO

Bausch + Lomb Corporation Shareholders' Equity for the year ending December 31, 2023: USD 6.85 B

Bausch + Lomb Corporation Shareholders' Equity is USD 6.85 B for the year ending December 31, 2023, a -2.60% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Bausch + Lomb Corporation Shareholders' Equity for the year ending December 31, 2022 was USD 7.03 B, a -24.61% change year over year.
  • Bausch + Lomb Corporation Shareholders' Equity for the year ending December 31, 2021 was USD 9.33 B, a -5.94% change year over year.
  • Bausch + Lomb Corporation Shareholders' Equity for the year ending December 31, 2020 was USD 9.92 B, a -0.41% change year over year.
  • Bausch + Lomb Corporation Shareholders' Equity for the year ending December 31, 2019 was USD 9.96 B.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
Toronto Stock Exchange: BLCO.TO

Bausch + Lomb Corporation

CEO Mr. Brenton L. Saunders J.D.
IPO Date May 6, 2022
Location Canada
Headquarters 520 Applewood Crescent
Employees 13,000
Sector Consumer Discretionary
Industries
Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Similar companies

PET.TO

Pet Valu Holdings Ltd.

USD 18.36

3.15%

DNTL.TO

dentalcorp Holdings Ltd.

USD 5.48

-0.17%

BHC.TO

Bausch Health Companies Inc.

USD 7.49

1.16%

StockViz Staff

January 15, 2025

Any question? Send us an email